Metabolism · Phase 2-3 · pulled 2026-11-06

Obesity: trial sites and investigators

25 sites and 10 investigators from 300 completed and terminated Phase 2-3 trials of obesity (last 12 years), plus 300 trials recruiting now.

A cited data summary, not a recommendation to select or exclude any site. Every line links to the registry record behind it.

Sites

Sites are listed in the registry's own order: comparable trials listed (most first), ties by latest completion, then name. The Sitecite score is a second column. “Competing now” counts recruiting, active and not-yet-recruiting trials in the same indication at that site.

Obesity: sites in the registry's trial-count order, with the Sitecite score as a second column
#	Site	Comparable trials listed	Trials (ClinicalTrials.gov)	Latest completion	Competing now	Score (0-100)
1	StudyMetrix Research City of Saint Peters, United States · 3 spellings merged	25 24 completed, 1 terminated	NCT06603571 NCT05929079 NCT05882045 6 trials with titles NCT06603571 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes completed 2026-09-14 NCT05929079 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight completed 2026-06-16 NCT05882045 A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease completed 2026-05-14 NCT06683508 A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight completed 2026-05-04 NCT05929066 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight completed 2026-04-30 NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01	2026-09-14	20 NCT07919405 NCT07890376 NCT07037433 NCT07662122	93
2	L-MARC Research Center Louisville, United States · 5 spellings merged	25 25 completed, 0 terminated	NCT06683508 NCT06066528 NCT05803421 6 trials with titles NCT06683508 A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight completed 2026-05-04 NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01 NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk completed 2026-03-16 NCT06066515 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight completed 2026-02-20 NCT06979505 GV101 in Healthy Obese Participants completed 2026-01-28 NCT06047548 A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities completed 2026-01-20	2026-05-04	7 NCT07477704 NCT07684235 NCT06858839 NCT07639021	92
3	Diablo Clinical Research, Inc. Walnut Creek, United States · 7 spellings merged	24 22 completed, 2 terminated	NCT06603571 NCT06926842 NCT05929079 6 trials with titles NCT06603571 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes completed 2026-09-14 NCT06926842 Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) completed 2026-08-13 NCT05929079 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight completed 2026-06-16 NCT06683508 A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight completed 2026-05-04 NCT06373146 A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity completed 2026-04-02 NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01	2026-09-14	27 NCT07685808 NCT07533175 NCT07575932 NCT07595549	89
4	Velocity Clinical Research, Dallas Dallas, United States · 6 spellings merged	22 20 completed, 2 terminated	NCT06628362 NCT06603571 NCT07081958 6 trials with titles NCT06628362 A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus completed 2026-10-02 NCT06603571 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes completed 2026-09-14 NCT07081958 A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity completed 2026-07-30 NCT06077864 A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) completed 2026-06-30 NCT05929079 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight completed 2026-06-16 NCT06683508 A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight completed 2026-05-04	2026-10-02	19 NCT07823608 NCT07282600 NCT07890376 NCT07477704	91
5	PharmQuest Life Sciences LLC Greensboro, United States · 6 spellings merged	21 20 completed, 1 terminated	NCT06603571 NCT06926842 NCT06683508 6 trials with titles NCT06603571 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes completed 2026-09-14 NCT06926842 Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) completed 2026-08-13 NCT06683508 A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight completed 2026-05-04 NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk completed 2026-03-16 NCT06662539 Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities completed 2026-03-07 NCT06131437 A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight completed 2026-01-09	2026-09-14	17 NCT07595549 NCT07794579 NCT07845500 NCT07282600	93
6	Peking University People's Hospital Beijing, China · 6 spellings merged	19 19 completed, 0 terminated	NCT06649045 NCT06066528 NCT06939296 6 trials with titles NCT06649045 A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight completed 2026-07-30 NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01 NCT06939296 A Research Study of VCT220 in Adult Chinese Participants With Obesity completed 2026-03-31 NCT06704581 A Study of BGM0504 Injection in Participants With Obesity or Overweight completed 2026-03-17 NCT06066515 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight completed 2026-02-20 NCT06184568 A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity completed 2026-02-09	2026-07-30	24 NCT07874633 NCT07648225 NCT07792954 NCT07670416	100
7	Iowa Diabetes and Endocrinology Research Center West Des Moines, United States · 4 spellings merged	17 15 completed, 2 terminated	NCT06603571 NCT06926842 NCT06077864 6 trials with titles NCT06603571 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes completed 2026-09-14 NCT06926842 Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) completed 2026-08-13 NCT06077864 A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) completed 2026-06-30 NCT05882045 A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease completed 2026-05-14 NCT06683508 A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight completed 2026-05-04 NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk completed 2026-03-16	2026-09-14	11 NCT07919405 NCT07794579 NCT07392190 NCT07890376	97
8	Accellacare Wilmington, United States · 11 spellings merged	16 16 completed, 0 terminated	NCT06628362 NCT07081958 NCT06649045 6 trials with titles NCT06628362 A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus completed 2026-10-02 NCT07081958 A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity completed 2026-07-30 NCT06649045 A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight completed 2026-07-30 NCT06388187 A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight completed 2026-04-22 NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01 NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk completed 2026-03-16	2026-10-02	24 NCT07575399 NCT07575932 NCT07919678 NCT07595549	93
9	Consano Clinical Research, LLC Shavano Park, United States · 3 spellings merged	16 15 completed, 1 terminated	NCT06628362 NCT06926842 NCT07081958 6 trials with titles NCT06628362 A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus completed 2026-10-02 NCT06926842 Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) completed 2026-08-13 NCT07081958 A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity completed 2026-07-30 NCT05882045 A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease completed 2026-05-14 NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01 NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk completed 2026-03-16	2026-10-02	25 NCT07575932 NCT07919678 NCT07919405 NCT07794579	90
10	Catalina Research Institute, LLC Montclair, United States · 3 spellings merged	15 13 completed, 2 terminated	NCT06628362 NCT06077864 NCT06737042 6 trials with titles NCT06628362 A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus completed 2026-10-02 NCT06077864 A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) completed 2026-06-30 NCT06737042 Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants completed 2026-02-27 NCT06979505 GV101 in Healthy Obese Participants completed 2026-01-28 NCT06309992 A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD) completed 2025-12-02 NCT04880031 A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension completed 2025-10-27	2026-10-02	6 NCT07919405 NCT07400653 NCT07351058 NCT07684235	90
11	Lillestol Research Fargo, United States · 3 spellings merged	15 15 completed, 0 terminated	NCT05929079 NCT05929066 NCT06373146 6 trials with titles NCT05929079 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight completed 2026-06-16 NCT05929066 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight completed 2026-04-30 NCT06373146 A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity completed 2026-04-02 NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk completed 2026-03-16 NCT06979505 GV101 in Healthy Obese Participants completed 2026-01-28 NCT06584916 A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) completed 2025-11-21	2026-06-16	9 NCT07794579 NCT07282600 NCT07662122 NCT07571109	100
12	Encompass Clinical Research Spring Valley, United States · 4 spellings merged	14 14 completed, 0 terminated	NCT06628362 NCT07081958 NCT06066528 6 trials with titles NCT06628362 A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus completed 2026-10-02 NCT07081958 A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity completed 2026-07-30 NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01 NCT06066515 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight completed 2026-02-20 NCT06979505 GV101 in Healthy Obese Participants completed 2026-01-28 NCT06047548 A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities completed 2026-01-20	2026-10-02	7 NCT07282600 NCT07353931 NCT07037433 NCT07351058	95
13	New Horizon Research Center Miami, United States · 2 spellings merged	14 13 completed, 1 terminated	NCT06603571 NCT06683508 NCT05929066 6 trials with titles NCT06603571 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes completed 2026-09-14 NCT06683508 A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight completed 2026-05-04 NCT05929066 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight completed 2026-04-30 NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01 NCT06066515 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight completed 2026-02-20 NCT06047548 A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities completed 2026-01-20	2026-09-14	11 NCT07575399 NCT07575932 NCT07282600 NCT07392190	93
14	The Second Affiliated Hospital of Nanjing Medical University Nanjing, China · 3 spellings merged	14 13 completed, 1 terminated	NCT06077864 NCT06066528 NCT06066515 6 trials with titles NCT06077864 A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) completed 2026-06-30 NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01 NCT06066515 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight completed 2026-02-20 NCT06214741 A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight completed 2026-01-28 NCT05872620 A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes completed 2025-08-08 NCT06041217 A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range completed 2025-05-07	2026-06-30	26 NCT07874633 NCT07792954 NCT07794579 NCT07282600	98
15	University of North Carolina Medical Center Chapel Hill, United States · 5 spellings merged	14 14 completed, 0 terminated	NCT06077864 NCT05803421 NCT06046443 6 trials with titles NCT06077864 A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) completed 2026-06-30 NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk completed 2026-03-16 NCT06046443 A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity completed 2026-02-09 NCT06131437 A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight completed 2026-01-09 NCT06062069 A Study of CT-868 in Type 1 Diabetes Mellitus completed 2025-07-07 NCT05514535 A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) completed 2025-04-09	2026-06-30	7 NCT07392190 NCT07881432 NCT07011667 NCT05567796	95
16	Velocity Clinical Research, Westlake Los Angeles, United States · 7 spellings merged	14 14 completed, 0 terminated	NCT06077864 NCT05929079 NCT05882045 6 trials with titles NCT06077864 A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) completed 2026-06-30 NCT05929079 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight completed 2026-06-16 NCT05882045 A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease completed 2026-05-14 NCT06373146 A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity completed 2026-04-02 NCT06897202 A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM completed 2026-03-18 NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk completed 2026-03-16	2026-06-30	2 NCT07845500 NCT05869903	100
17	Juno Research Houston, United States · 3 spellings merged	13 13 completed, 0 terminated	NCT06628362 NCT06926842 NCT07081958 6 trials with titles NCT06628362 A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus completed 2026-10-02 NCT06926842 Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) completed 2026-08-13 NCT07081958 A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity completed 2026-07-30 NCT05929066 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight completed 2026-04-30 NCT06373146 A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity completed 2026-04-02 NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01	2026-10-02	11 NCT07282600 NCT06897475 NCT07881458 NCT07392190	94
18	Arcturus Healthcare , PLC, Troy Internal Medicine Research Division Troy, United States · 4 spellings merged	13 12 completed, 1 terminated	NCT06603571 NCT05536804 NCT06683508 6 trials with titles NCT06603571 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes completed 2026-09-14 NCT05536804 A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes completed 2026-07-30 NCT06683508 A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight completed 2026-05-04 NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk completed 2026-03-16 NCT06584916 A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) completed 2025-11-21 NCT06230523 A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight completed 2025-08-14	2026-09-14	18 NCT07575399 NCT07794579 NCT07202884 NCT07392190	92
19	Rochester Clinical Research, LLC Rochester, United States · 4 spellings merged	13 12 completed, 1 terminated	NCT06603571 NCT05882045 NCT06683508 6 trials with titles NCT06603571 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes completed 2026-09-14 NCT05882045 A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease completed 2026-05-14 NCT06683508 A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight completed 2026-05-04 NCT05929066 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight completed 2026-04-30 NCT06717425 A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity completed 2026-01-12 NCT06230523 A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight completed 2025-08-14	2026-09-14	19 NCT07575399 NCT07685808 NCT07595549 NCT07794579	90
20	Tribe Clinical Research, LLC Greenville, United States · 6 spellings merged	13 13 completed, 0 terminated	NCT06603571 NCT06077864 NCT05929079 6 trials with titles NCT06603571 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes completed 2026-09-14 NCT06077864 A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) completed 2026-06-30 NCT05929079 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight completed 2026-06-16 NCT05882045 A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease completed 2026-05-14 NCT06683508 A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight completed 2026-05-04 NCT05929066 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight completed 2026-04-30	2026-09-14	13 NCT07685808 NCT07845500 NCT07890376 NCT07477704	100
21	Palm Research Center Sunset Las Vegas, United States · 9 spellings merged	13 13 completed, 0 terminated	NCT06926842 NCT05882045 NCT05929066 6 trials with titles NCT06926842 Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) completed 2026-08-13 NCT05882045 A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease completed 2026-05-14 NCT05929066 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight completed 2026-04-30 NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk completed 2026-03-16 NCT06584916 A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) completed 2025-11-21 NCT05936151 A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes completed 2025-10-21	2026-08-13	16 NCT07575932 NCT07369011 NCT07881432 NCT07783802	97
22	The First Affiliated Hospital of Henan University of Science and Technology Luoyang, China · 8 spellings merged	13 12 completed, 1 terminated	NCT07791524 NCT06077864 NCT06066528 6 trials with titles NCT07791524 Phase 2 Study of MWN109 Tablet in Participants With Overweight or Obesity completed 2026-07-09 NCT06077864 A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) completed 2026-06-30 NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01 NCT07791654 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight or Obesity completed 2026-03-21 NCT06066515 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight completed 2026-02-20 NCT06214741 A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight completed 2026-01-28	2026-07-09	14 NCT07792954 NCT07353931 NCT07881432 NCT07850063	98
23	Jinan Central Hospital Jinan, China · 5 spellings merged	13 13 completed, 0 terminated	NCT06738979 NCT05872620 NCT07020884 6 trials with titles NCT06738979 A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects completed 2026-05-26 NCT05872620 A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes completed 2025-08-08 NCT07020884 A Study of ZT002 Injection With Subjects With Overweight or Obesity completed 2025-05-29 NCT06041217 A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range completed 2025-05-07 NCT05996848 A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight completed 2025-02-22 NCT05890976 Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3) completed 2025-01-16	2026-05-26	29 NCT07792954 NCT07670416 NCT07794579 NCT07282600	100
24	Clinical Trials of Texas, LLC San Antonio, United States · 10 spellings merged	13 13 completed, 0 terminated	NCT07011797 NCT05803421 NCT06662539 6 trials with titles NCT07011797 A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants completed 2026-04-09 NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk completed 2026-03-16 NCT06662539 Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities completed 2026-03-07 NCT05669599 Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus completed 2025-12-16 NCT06309992 A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD) completed 2025-12-02 NCT05931367 A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee completed 2025-11-14	2026-04-09	7 NCT07881432 NCT07477704 NCT05556512 NCT07684235	97
25	Great Lakes Clinical Trials - Ravenswood Chicago, United States · 6 spellings merged	12 11 completed, 1 terminated	NCT06603571 NCT06926842 NCT06683508 6 trials with titles NCT06603571 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes completed 2026-09-14 NCT06926842 Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) completed 2026-08-13 NCT06683508 A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight completed 2026-05-04 NCT06588296 Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight completed 2026-04-23 NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk completed 2026-03-16 NCT06662539 Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities completed 2026-03-07	2026-09-14	16 NCT07919678 NCT07919405 NCT07794579 NCT07392190	88

Investigators

Principal investigators and study chairs of the comparable trials, most trials first. Papers are matched on name, affiliation and condition; the match confidence is shown on each.

Obesity: principal investigators and study chairs of the comparable trials, with matched papers
#	Investigator	Comparable trials	Trials (ClinicalTrials.gov)	Papers (PubMed)
1	Aaron Kelly University of Minnesota	2	NCT04873245 NCT04298203	PMID 41936497 Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2026 · Medium match
2	Valentina Ivezaj Yale University	2	NCT04605081 NCT05157698	PMID 42057441 The International journal of eating disorders, 2026 · High match PMID 41136272 Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, 2026 · High match
3	hany moustafa ibraheem alzafer hospital , najran , KSA	2	NCT07820111 NCT06186102	No paper matched at High or Medium confidence
4	XIAOJUN CHEN Obstetrics & Gynecology Hospital of Fudan University	2	NCT05316467 NCT05172999	PMID 42983712 BMC pregnancy and childbirth, 2026 · High match PMID 42945651 Maturitas, 2026 · High match
5	Jack A Yanovski Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	2	NCT05017571 NCT04883346	PMID 42858897 The Journal of nutrition, 2026 · High match PMID 42538646 Pediatric obesity, 2026 · High match PMID 41797473 Obesity (Silver Spring, Md.), 2026 · High match
6	Linong Ji Peking University People's Hospital	2	NCT07020884 NCT05813795	PMID 42978062 Journal of diabetes, 2026 · High match PMID 42862437 Advances in therapy, 2026 · High match PMID 42839752 Diabetes, obesity & metabolism, 2026 · High match
7	Jacob Eifer Møller Odense University Hospital	2	NCT05084235 NCT05042973	No paper matched at High or Medium confidence
8	Ping Jin The Third Xiangya Hospital of Central South University	2	NCT06350812 NCT06195813	PMID 42843337 Cell metabolism, 2026 · High match PMID 42729817 Frontiers in immunology, 2026 · High match PMID 42712041 Diabetes, obesity & metabolism, 2026 · High match
9	Carlos M Grilo Yale University	2	NCT03926052 NCT03946111	PMID 42687891 Research square, 2026 · High match PMID 42668311 International journal of obesity (2005), 2026 · High match PMID 42057441 The International journal of eating disorders, 2026 · High match
10	Marc Donath University Hospital Basel, Department of Endocrinology, Diabetes and Metabolism	2	NCT04510493 NCT04227769	No paper matched at High or Medium confidence

How to read this

Sites are counted from the facility lists on the registry record, with spelling variants merged. “Listed on the trial” means the registry shows the site as a location; it is not a count of patients enrolled. The method, the formula and the published tests.

Want this for your own protocol or your CRO's list?

Leave your indication and the CRO's names. We reply by email with each one checked against these records.